It's roughly 2 weeks from when I expect the company will be conducting their 3rd quarter webcast. I expect the financials will be positive, on sales of Elahere, but more importantly, I believe they'll reveal upcoming conference appearances which should reveal new positive data in ongoing trials. Greater earnings will certainly help the share price, but new drugs approaching approval boosts the long term potential, and if we should be headed toward a buyout, it certainly substantially increases what the purchase price should be.
Gary
Bullish
Market Data 
Markets 
AI
